Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x100px
Organisation › Details

CRISPR Therapeutics AG (Nasdaq: CRSP)

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company’s scientific founder Emmanuelle Charpentier, Ph.D., who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. *

 

Period Start 2013-01-01 established
  Group CRISPR Therapeutics (Group)
Product Industry CRISPR gene editing technology
Persons Person Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
  Person 2 Prasad, Raju (CRISPR Therapeutics 202303– CFO before William Blair)
     
Region Region Basel BS
  Country Switzerland
  Street 36 Aeschenvorstadt
  City 4051 Basel BS
    Address record changed: 2024-01-05
     
Basic data Employees D: 101 to 500 (2023-12-31)
  Currency USD
  Annual sales 289,590,000 (revenue, collaboration, consolidated (2019) 2019-12-31)
  Profit -153,610,000 (2023-12-31)
  Cash 1,693,692,000 (2023-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2024-05-30

Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top